# Allarity Therapeutics, Inc.: financial statements, quarterly

ALLR · Nasdaq · CIK 1860657 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/allr.md) · [Financials](/companies/allr/financials.md) · [Filings](/companies/allr/filings.md) · [Insiders](/companies/allr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/allr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-017371.md) | [0.0](/filings/0001437749-26-027830.md) | not reported | not reported | [0.0](/filings/0001437749-26-017371.md) | [0.0](/filings/0001437749-26-027830.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.9](/filings/0001437749-24-035314.md) | [2.6 d](/filings/0001437749-25-010198.md) | [2.2](/filings/0001437749-25-015780.md) | [1.1](/filings/0001437749-25-027146.md) | [1.0](/filings/0001437749-25-035003.md) | [1.8 d](/filings/0001437749-26-010310.md) | [1.4](/filings/0001437749-26-017371.md) | [2.3](/filings/0001437749-26-027830.md) | [1.2](/filings/0001437749-25-035003.md) | [1.7 d](/filings/0001437749-26-010310.md) | [1.3](/filings/0001437749-26-017371.md) | [1.3](/filings/0001437749-26-027830.md) |
| Operating income | $m | [(4.4)](/filings/0001437749-24-035314.md) | [(4.9) d](/filings/0001437749-25-010198.md) | [(4.2)](/filings/0001437749-25-015780.md) | [(3.4)](/filings/0001437749-25-027146.md) | [(12.3)](/filings/0001437749-25-035003.md) | [(7.3) d](/filings/0001437749-26-010310.md) | [(3.0)](/filings/0001437749-26-017371.md) | [(4.1)](/filings/0001437749-26-027830.md) | [(2.5)](/filings/0001437749-25-035003.md) | [(2.9) d](/filings/0001437749-26-010310.md) | [(2.7)](/filings/0001437749-26-017371.md) | [(2.7)](/filings/0001437749-26-027830.md) |
| Interest expense | $m | [0.0](/filings/0001213900-23-086382.md) | [0.2 d](/filings/0001213900-24-020864.md) | [0.1](/filings/0001213900-24-042997.md) | [0.4](/filings/0001437749-25-027146.md) | [0.1](/filings/0001437749-25-035003.md) | [0.1 d](/filings/0001437749-26-010310.md) | [0.1](/filings/0001437749-26-017371.md) | [0.0](/filings/0001437749-26-027830.md) | [0.1](/filings/0001437749-25-035003.md) | [0.1 d](/filings/0001437749-26-010310.md) | [0.2](/filings/0001437749-26-017371.md) | [0.7](/filings/0001437749-26-027830.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-035314.md) | [0.1 d](/filings/0001437749-25-010198.md) | [(0.0)](/filings/0001437749-25-015780.md) | [0.0](/filings/0001437749-25-027146.md) | [(0.4)](/filings/0001437749-25-035003.md) | [0.0 d](/filings/0001437749-26-010310.md) | [0.0](/filings/0001437749-25-015780.md) | [0.0](/filings/0001437749-25-027146.md) | [0.0](/filings/0001437749-25-035003.md) | [0.0 d](/filings/0001437749-26-010310.md) | not reported | not reported |
| Net income | $m | [(4.4)](/filings/0001437749-24-035314.md) | [(1.7) d](/filings/0001437749-25-010198.md) | [(3.8)](/filings/0001437749-25-035003.md) | [(1.6)](/filings/0001437749-25-035003.md) | [(11.6)](/filings/0001437749-25-035003.md) | [(7.5) d](/filings/0001437749-26-010310.md) | [(2.7)](/filings/0001437749-26-027830.md) | [(2.3)](/filings/0001437749-26-027830.md) | [(2.8)](/filings/0001437749-25-035003.md) | [(3.4) d](/filings/0001437749-26-010310.md) | [(2.8)](/filings/0001437749-26-027830.md) | [(3.4)](/filings/0001437749-26-027830.md) |
| Diluted EPS | $ per share | [(2.03)](/filings/0001213900-23-086382.md) | not reported | [(22.14)](/filings/0001213900-24-042997.md) | [(0.11)](/filings/0001213900-24-065252.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(1346.09)](/filings/0001437749-24-035314.md) | not reported | [(664.16)](/filings/0001437749-25-015780.md) | [(3.34)](/filings/0001437749-25-027146.md) | [(7.71)](/filings/0001437749-25-035003.md) | not reported | [(0.25)](/filings/0001437749-26-017371.md) | [(0.15)](/filings/0001437749-26-027830.md) | [(0.19)](/filings/0001437749-25-035003.md) | not reported | [(0.17)](/filings/0001437749-26-017371.md) | [(0.21)](/filings/0001437749-26-027830.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.4](/filings/0001213900-23-086382.md) | [0.2](/filings/0001437749-25-010198.md) | [0.3](/filings/0001213900-24-042997.md) | [19.2](/filings/0001213900-24-065252.md) | not reported | [19.5](/filings/0001437749-26-010310.md) | [25.2](/filings/0001437749-26-017371.md) | [17.8](/filings/0001437749-26-027830.md) | [16.9](/filings/0001437749-25-035003.md) | [14.7](/filings/0001437749-26-027830.md) | [19.8](/filings/0001437749-26-017371.md) | [17.0](/filings/0001437749-26-027830.md) |
| Current assets | $m | [4.4](/filings/0001213900-23-086382.md) | [2.0](/filings/0001437749-25-010198.md) | [2.3](/filings/0001213900-24-042997.md) | [21.3](/filings/0001213900-24-065252.md) | [20.4](/filings/0001437749-24-035314.md) | [22.3](/filings/0001437749-26-010310.md) | [29.4](/filings/0001437749-25-015780.md) | [20.9](/filings/0001437749-25-027146.md) | [20.5](/filings/0001437749-25-035003.md) | [17.9](/filings/0001437749-26-027830.md) | [34.5](/filings/0001437749-26-017371.md) | [31.7](/filings/0001437749-26-027830.md) |
| Total assets | $m | [13.9](/filings/0001213900-23-086382.md) | [11.9](/filings/0001437749-25-010198.md) | [12.0](/filings/0001213900-24-042997.md) | [30.9](/filings/0001213900-24-065252.md) | [20.4](/filings/0001437749-24-035314.md) | [22.7](/filings/0001437749-26-010310.md) | [29.7](/filings/0001437749-25-015780.md) | [21.2](/filings/0001437749-25-027146.md) | [20.8](/filings/0001437749-25-035003.md) | [18.3](/filings/0001437749-26-027830.md) | [34.9](/filings/0001437749-26-017371.md) | [32.1](/filings/0001437749-26-027830.md) |
| Current liabilities | $m | [15.7](/filings/0001213900-23-086382.md) | [14.2](/filings/0001437749-25-010198.md) | [18.0](/filings/0001213900-24-042997.md) | [10.6](/filings/0001213900-24-065252.md) | [7.4](/filings/0001437749-24-035314.md) | [10.8](/filings/0001437749-26-010310.md) | [11.1](/filings/0001437749-25-015780.md) | [9.0](/filings/0001437749-25-027146.md) | [8.8](/filings/0001437749-25-035003.md) | [8.4](/filings/0001437749-26-027830.md) | [28.0](/filings/0001437749-26-017371.md) | [28.6](/filings/0001437749-26-027830.md) |
| Total liabilities | $m | [17.3](/filings/0001213900-23-086382.md) | [14.6](/filings/0001437749-25-010198.md) | [18.4](/filings/0001213900-24-042997.md) | [11.0](/filings/0001213900-24-065252.md) | [7.4](/filings/0001437749-24-035314.md) | [10.8](/filings/0001437749-26-010310.md) | [11.1](/filings/0001437749-25-015780.md) | [9.0](/filings/0001437749-25-027146.md) | [8.8](/filings/0001437749-25-035003.md) | [8.4](/filings/0001437749-26-027830.md) | [28.0](/filings/0001437749-26-017371.md) | [28.6](/filings/0001437749-26-027830.md) |
| Long-term debt | $m | [2.7](/filings/0001213900-23-086382.md) | [2.7](/filings/0001437749-25-010198.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.3](/filings/0001213900-24-020864.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-027830.md) | [20.1](/filings/0001437749-26-017371.md) | [20.9](/filings/0001437749-26-027830.md) |
| Shareholders' equity | $m | [(3.4)](/filings/0001437749-24-035314.md) | [(2.8)](/filings/0001437749-26-010310.md) | [(6.5)](/filings/0001437749-25-035003.md) | [19.8](/filings/0001437749-25-035003.md) | [13.0](/filings/0001437749-25-035003.md) | [11.8](/filings/0001437749-26-027830.md) | [18.7](/filings/0001437749-26-027830.md) | [12.2](/filings/0001437749-26-027830.md) | [12.0](/filings/0001437749-25-035003.md) | [9.8](/filings/0001437749-26-027830.md) | [6.9](/filings/0001437749-26-027830.md) | [3.5](/filings/0001437749-26-027830.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,376) d](/filings/0001437749-24-035314.md) | [(1,672) d](/filings/0001437749-25-010198.md) | [(1,399)](/filings/0001437749-25-015780.md) | [(7,304) d](/filings/0001437749-25-027146.md) | [(5,443) d](/filings/0001437749-25-035003.md) | [(3,206) d](/filings/0001437749-26-010310.md) | [(2,686)](/filings/0001437749-26-017371.md) | [(5,481) d](/filings/0001437749-26-027830.md) | [(3,410) d](/filings/0001437749-25-035003.md) | [(3,243) d](/filings/0001437749-26-010310.md) | [(4,493)](/filings/0001437749-26-017371.md) | [(2,564) d](/filings/0001437749-26-027830.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-017371.md) | [0.0 d](/filings/0001437749-26-027830.md) | not reported | not reported | [64.0](/filings/0001437749-26-017371.md) | [0.0 d](/filings/0001437749-26-027830.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001437749-25-035003.md) | [0.0 d](/filings/0001437749-26-010310.md) | [0.0](/filings/0001437749-26-017371.md) | [2,565 d](/filings/0001437749-26-027830.md) | [141 d](/filings/0001437749-25-035003.md) | [484 d](/filings/0001437749-26-010310.md) | [262](/filings/0001437749-26-017371.md) | [0.0 d](/filings/0001437749-26-027830.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2020-09-30) | period not labelled (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.7](/filings/0001213900-22-027297.md) | [5.0](/filings/0001213900-22-062840.md) | [7.8](/filings/0001213900-22-072355.md) | [0.2](/filings/0001213900-23-038609.md) | [0.1](/filings/0001213900-23-066893.md) | [0.0](/filings/0001213900-23-086382.md) | [0.0](/filings/0001213900-24-042997.md) | [0.0](/filings/0001213900-24-065252.md) | [2.5](/filings/0001213900-23-086382.md) | [0.2](/filings/0001213900-24-042997.md) | [15.0](/filings/0001213900-24-065252.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 15,910,724 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001437749-26-027830.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.